On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. Read More on REGN: Regeneron Pharmaceuticals NewsMORE Related Stocks Indices ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ:SNY) have reported positive outcomes from a Phase 3 trial of Dupixent (dupilumab) in patients with ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...